The Fight for Drug Pricing Transparency

California Attorney General Rob Bonta led a coalition of 21 attorneys general in filing an amicus brief supporting Oregon's House Bill 4005, which mandates pharmaceutical manufacturers to disclose pricing information for new and existing drugs. This law, passed in 2018, aims to enhance drug price transparency and hold companies accountable for price increases. The Pharmaceutical Research and Manufacturers Association challenged the law's constitutionality, leading to a federal court ruling in favor of PhRMA, prompting Oregon to appeal to the Ninth Circuit. Bonta emphasized the urgency of state-level action against rising drug prices, which threaten access to healthcare and can lead to severe health consequences. He noted that high prescription costs can result in worsening medical conditions and even fatalities. The coalition's brief argues that state laws like Oregon's are essential for protecting residents from the adverse effects of escalating drug prices. California's Senate Bill 17, similar to Oregon's law, requires manufacturers to report price increases, allowing state agencies to analyze the impact of drug costs on health plan premiums. Both laws aim to create accountability among pharmaceutical companies and provide data to inform strategies for controlling drug prices. The issue of drug pricing is critical, as a significant portion of the American population has experienced the dire consequences of unaffordable medication. The coalition's efforts reflect a broader movement among states to promote transparency and accountability in drug pricing, ultimately seeking to safeguard public health and well-being.